High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrier

The combination of high-dose teriparatide with denosumab could represent an ideal intervention for postmenopausal women with osteoporosis at very high risk of fracture; cost is a concern, however.Medscape Medical News
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news